Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	3.45B +47.2%
Revenue (ttm)	941.44M +16.5%
Net Income	163.66M +83.3%
EPS	0.07 +86.2%
Shares Out	n/a
PE Ratio	21.11
Forward PE	17.25
Dividend	0.02 (1.58%)
Ex-Dividend Date	Jun 18, 2025

Volume	n/a
Average Volume	n/a
Open	1.320
Previous Close	1.210
Day's Range	1.320 - 1.320
52-Week Range	0.845 - 1.600
Beta	n/a
RSI	55.87
Earnings Date	Mar 25, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,815
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2025, FRA:S2P's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 83.32%.

Financial numbers in CNY